FRANK PALLONE, JR., NEW JERSEY
CHAIRMAN

CATHY McMORRIS RODGERS, WASHINGTON
RANKING MEMBER

ONE HUNDRED SEVENTEENTH CONGRESS

Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

March 10, 2022

HEARING NOTICE

TO: **Members of the Subcommittee on Health**

FROM: **Anna G. Eshoo, Chairwoman**

SUBJECT: **Subcommittee Hearing on "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight"**

The Subcommittee on Health of the Committee on Energy and Commerce will hold a hybrid hearing that includes both in-person and remote attendance on **Thursday, March 17, 2022, at 10:30 a.m. (EDT)**. The hearing is entitled, "The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight." Witnesses will be by invitation only.

This is a legislative hearing that will focus on the following attached bills:

- **H.R. 1730**, the "Speeding Therapy Access Today Act of 2021" (*Reps. Bilirakis (R-FL) and Butterfield (D-NC) on 03/10/2021*)
- **H.R. 2565**, the "FDA Modernization Act of 2021" (*Reps. Buchanan (R-FL), Luria (D-VA), Mace (R-SC), Sherrill (D-NJ), and Boyle (D-PA) on 04/15/2021*)
- **H.R. 3085**, the "Equity in Neuroscience and Alzheimer's Clinical Trials Act of 2021" or the "ENACT Act of 2021" (*Reps. Blunt Rochester (D-DE), Herrera Beutler (R-WA), Curtis (R-UT), Smith (R-NJ), and Waters (D-CA) on 05/11/2021*)
- **H.R. 3927**, the "Manufacturing API, Drugs, and Excipients in America Act" or the "MADE in America Act" (*Rep. Carter (R-GA) and eight other original cosponsors on 06/16/2021*)
- **H.R. 4472**, the "Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021" or the "BENEFIT Act of 2021" (*Reps. Matsui (D-CA) and Wenstrup (R-OH) on 07/16/2021*)
- **H.R. 4511**, the "FDA Advancing Collection of Transformative Science Act" or the "FACTS Act" (*Reps. Burgess (R-TX) and Craig (D-MN) on 07/19/2021*)
- **H.R. 5030**, the "Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act" or the "DIVERSE Trials Act" (*Reps. Ruiz (D-CA) and Bucshon (R-IN) on 08/13/2021*)

- **H.R. 5566**, the "Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021" or the "FORWARD Act of 2021" (*Reps. McCarthy (R-CA), Schweikert (R-AZ), Bass (D-CA), and O'Halleran (D-AZ) on 10/12/2021*)
- **H.R. 5585**, the "Advanced Research Project Agency–Health Act" or the "ARPA-H Act" (*Rep. Eshoo (D-CA) on 10/15/2021*)
- **H.R. 6000**, the "Cures 2.0 Act" (*Reps. DeGette (D-CO) and Upton (R-MI) on 11/17//2021*)
- **H.R. 6584**, the "Diverse and Equitable Participation in Clinical Trials Act" or the "DEPICT Act" (*Reps. Eshoo, Fitzpatrick (R-PA), and Kelly (D-IL) on 02/03/2022*)
- **H.R. 6888**, the "Helping Experts Accelerate Rare Treatments Act of 2022" (*Reps. Tonko (D-NY) and McKinley (R-WV) on 03/01/2022*)
- **H.R. 6963**, the "Accelerated Approval Integrity Act of 2022" (*Rep. Pallone (D-NJ) on 03/07/2022*)
- **H.R. 6972**, the "Give Kids a Chance Act" (*Reps. Butterfield and McCaul (R-TX) on 03/08/2022*)
- **H.R. 6973**, the "Enhanced Access to Affordable Medicines Act" (*Rep. Carter on 03/08/2022*)
- **H.R. 6988**, the "Drug Manufacturing Innovation Act" (*Reps. Levin (D-CA) and Joyce (R-PA) on 03/08/2022*)
- **H.R. 6996**, the "Accelerating Access for Patients Act" (*Rep. Rodgers (R-WA) on 03/08/2022*)
- **H.R. 7006**, the "Improving the Nation's Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act" or the "INSPECTIONS Act" (*Reps. Griffith (R-VA) and Welch (D-VT) on 03/09/2022*)
- **H.R. 7008**, the "Pre-Approval Information Exchange Act" (*Rep. Guthrie (R-KY) on 03/09/2022*)
- **H.R. 7032**, the "Increasing Transparency in Generic Drug Applications Act" (*Rep. Kuster (D-NH) on 03/09/2022*)
- **H.R. 7035**, the "Biologics Market Transparency Act" (*Reps. Manning (D-NC) and Hudson (R-NC) on 03/09/2022*)
- **H.R. 7047**, a bill to amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes (*Rep. Schrader (D-OR) on 03/09/2022*)

This hearing will take place in the John D. Dingell Room, 2123 of the Rayburn House Office Building, as well as remotely using Cisco WebEx online video conferencing. Members will receive WebEx participant access information by email before the hearing. No staff from member offices will be allowed in the Committee room. **However, one staffer from each member's office may join the hearing remotely as an attendee.** Each designated staff attendee must **register** at the provided link **by no later than Wednesday, March 16, 2022, at 12 p.m. (EDT)**. The public may view this hearing via live webcast on the Committee's website: http://energycommerce.house.gov.

For members planning to attend in person, the Committee notes that this hearing is being held during the COVID-19 pandemic, therefore the Committee will adhere to the greatest extent possible to the safety guidelines issued by the Centers for Disease Control and Prevention and the Attending Physician of the Capitol. Guidelines regarding the conduct of this hearing were previously distributed.

The bipartisan staff briefing for this hearing will be held by video conference using Microsoft Teams on Tuesday, March 15, 2022, at 2:30 p.m. (EDT). The Democratic staff briefing will be held immediately following the bipartisan briefing. The Republican staff briefing will be announced separately. Information for these briefings will be sent out later this week.

If you have any questions, please contact Meghan Mullon with the Committee staff at meghan.mullon@mail.house.gov.

Currently the U.S. House of Representatives Office Buildings, as well as the U.S. Capitol complex, are closed to the public. Official meetings of the Committee on Energy and Commerce, or its subcommittees, are broadcast and available on the Committee's website: www.energycommerce.house.gov.